I’m pleased to report that we came out of the meeting with the same plan that we went in with and we feel like we have a very clear path toward registration. We plan to commence the Phase III program in the next couple of months. I look forward to sharing more details about the program at that time.
Additionally, our abstract on the Phase II study of pimavanserin in AD Psychosis was recently accepted for presentation in a symposium at the Clinical Trials on Alzheimer’s Disease or CTAD annual meeting. This meeting will be in Boston in the first week of November.
After the CTAD meeting, scientific experts will address the importance of serotonin in AD Psychosis. They will also discuss data from our Phase II study and they’ll review these results in the context of historical Alzheimer’s disease psychosis trials. So as we look ahead, we’re excited to share more data on AD Psychosis and we’re also excited about continuing to advance our core other CNS programs in development.